Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Tackling the Gradient: Applying Public Health Policies to Effectively Reduce Health Inequalities amongst Families and Children (GRADIENT)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Belgium,Belgium,Czechia,United Kingdom,Germany,Norway,Spain,Sweden,Iceland,Slovenia,Netherlands
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-04-01
End date: 2012-03-31
Duration (months): 36.0
Total project cost (EUR): 2368215.0
EU funding (EUR): 1881257.0
Participants: 12
Project status: CLOSED

Health inequalities are currently regarded as one of the most important public health challenges in the EU. There is however not sufficient knowledge of what actions are effective to reduce the gradient in health inequalities. 'Tackling the Gradient' aims to address this, to ensure that political momentum is maintained and that operational strategies can be developed to make progress on this issue. The focus of the research project will be on families and children, since the greatest impact on reducing the health gradient can be achieved through early life policy interventions and by creating equal opportunities during childhood and adolescence. This project involves the following components, which directly address the theme of the call: • Develop a common Evaluation Framework that can be applied across the EU to assess and determine what works. • Determine whether and why traditional public health and health promotion policy measures don’t reach or fail to change behaviours amongst the more socially deprived groups. • Explore some currently understudied protective factors (particularly the influence of social capital on children, adolescents and families) that could be important to tackling the health gradient. • Identify what targeted and universal policy approaches to protect families and children from falling into poverty and ill health are currently being applied, and appear to be effective in tackling the health inequalities gradient • Widely disseminate the outcomes and results to politicians and practitioners in the form of scientifically sound recommendations at the local, national and EU levels. The research will be undertaken by a consortium comprising of 34 members from 12 institutions across Europe. The work will be coordinated by EuroHealthNet, which has considerable expertise in managing EU projects in the area of health inequalities, and is well placed to feed research results into policy making processes at the national and EU level.

Keywords: health inequalities,gradient,policy,evaluation,impact on families and children,protective factors
Genomic Regulatory Systems of Human X-linked neurological diseases (NEUROXSYS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Norway,United Kingdom,United Kingdom,Germany,France,Germany,Australia,United Kingdom
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-06-01
End date: 2012-11-30
Duration (months): 42.0
Total project cost (EUR): 3970394.0
EU funding (EUR): 2997197.0
Participants: 9
Project status: CLOSED

NeuroXsys will generate regulatory maps and models of the human X chromosome based on evolutionary conservation, with special attention to genes and regions implicated in X-linked neurological diseases. Vertebrate chromosomes are subdivided into domains of genomic regulatory blocks (GRBs) and NeuroXsys aims to map all GRBs on the X chromosome through bioinformatic approaches, extract gene regulatory sequences, and model their activity through transgenic reporter assays in the zebrafish juvenile and adult brain. One of the major deliverables of this project will be the publication of an online database that achieves correlation of disease genes ordered with respect to their regulatory regions and their experimentally and bioinformatically assessed function. NeuroXsys will seek to identify human disease mutations in neural gene regulatory elements. Implicated elements will be studied as regulators at single cell resolution in the zebrafish and mouse brain, defining expression patterns driven by the normal and mutant human regulatory DNA sequences. NeuroXsys will generate a regulatory map of a human chromosome.

Keywords: x-chromosome,hcne,genomic regulatory blocks,conserved synteny,neurological diseases,long-range cis regulation,brain development
Sustaining research momentum over the coming decades: mentoring the next generation of researchers for tuberculosis. (TBSUSGENT)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Coordination and support actions
Countries involved: United Kingdom,Italy,India,South Africa,Canada,Germany
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-11-01
End date: 2012-10-31
Duration (months): 48.0
Total project cost (EUR): 1121393.29
EU funding (EUR): 999909.0
Participants: 7
Project status: CLOSED

Tuberculosis is an international public health crisis of catastrophic proportions. The relative lack of TB research and funded investigators over the last several decades has been acknowledged by the The Stop TB Partnership and Global Stop TB Plan. In order to sustain research momentum over the next few decades suitably qualified investigators, who are the next generation of TB researchers, particularly from developing countries, will have to be nurtured and supported. This proposal seeks to, by building on existing research and capacity development programmes, create a scientific fellowship programme focussed on activities encompassing poverty-related disease i.e. tuberculosis (TB). It seeks further to facilitate career progression of developing country clinical-scientists through a programme offering scientific training and a network of mentors.

Keywords: tuberculosis,capacity development,nascent researchers
Promotion and facilitation of international cooperation with Eastern European and Central Asian countries (EECALINK)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Coordination and support actions
Countries involved: Czechia,Italy,Poland,Hungary,Georgia,Kazakhstan,Belarus,Poland,Ukraine,Moldova, Republic of,Hungary,Russian Federation,Armenia,Uzbekistan
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-06-01
End date: 2011-11-30
Duration (months): 30.0
Total project cost (EUR): 679125.0
EU funding (EUR): 600000.0
Participants: 17
Project status: CLOSED

The EECAlink is a coordination action aimed at identification of joint research priorities of the EU and EECA countries and strengthening scientific collaboration among them. International Cooperation Partner Countries targeted by our proposal are: Armenia, Belarus, Georgia, Kazakhstan, Moldova, Russia, Ukraine and Uzbekistan. EECAlink represents (i) a measure of active encouragement of the international Health research related cooperation and allows (ii) strengthening of the existing bi-lateral scientific collaboration of all participating university/academia partners. Project consortium was balanced to be able to act as a pipe-line for communication of the (iii) research priorities of EECA countries to relevant EU policy makers and vice versa, (iv) help to coordinate future joint calls relevant to the Health Theme. Last, but not least, (v) to build capacities for proposal submission in FP7. EECAlink is proposed to run for 30 months. For the project communication and impact evaluation purposes, we have defined three major target stakeholder groups: 1. Policy makers – this target group is further divided into (i) European and (ii) national. The first stakeholder group represents a key element for creation of European added value through identification of joint research opportunities for future calls in the area of Health research 2. Universities and academia partners – the project is coordinated by the Charles University in Prague and represents a consortium of ten academic partners, who wish to both strengthen and extend their international collaboration in topics identified in FP7-TP Health programme 3. Wider RTD public – research and innovation managers and individual scientific group leaders from participating countries interested in submitting own FP7 proposals

Keywords: identification of joint research prioriteis,networking actions,fp7 project administration,eastern european and central asian countries
Mitochondrial dysfunction in neurodegenerative diseases: towards new therapeutics (MITOTARGET)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: France,United Kingdom,Germany,Germany,France,France,Germany,Germany,United Kingdom,Belgium,Netherlands,France,Germany,France,France,Germany,France
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-02-01
End date: 2012-03-31
Duration (months): 38.0
Total project cost (EUR): 10332037.6
EU funding (EUR): 5999980.0
Participants: 18
Project status: CLOSED

Mitochondrial dysfunction is a major hallmark of various neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, Huntington’s diseases or Amyotrophic Lateral Sclerosis (ALS). However linking mitochondrial dysfunction to the pathogenesis of some of these diseases still needs to be elucidated. Furthermore, in pathologies where this link is already established, the question remains whether specific targets or mechanisms involved in mitochondrial dysfunction will be amenable to therapeutic intervention. MitoTarget is an ambitious project aimed at providing solid data to better understand and exploit the circumstantial evidence linking mitochondrial dysfunction with neuronal dysfunction culminating in neurodegenerative disease. A 36 months translational research program will bring together a unique partnership between basic scientists, a seasoned team of clinical investigators and a SME that has identified a first-in-class compound, TRO19622, that targets mitochondria and has powerful neuroprotective and neuroregenerative activities. In parallel, and orchestrated by the SME that is the coordinator of the project, MitoTarget will bring together a more comprehensive insight into the mechanisms leading to mitochondrial impairments and establish their clinical relevance in a severe orphan neurodegenerative disease, ALS. If successful, it is expected that from this proof of principle a new class of therapeutic agents targeting the underlying mitochondrial dysfunction in neurons or their supporting cells will emerge. Results of the project have the potential to create a new paradigm for the drug discovery for neurodegenerative diseases.

Keywords: neurodegenerative disease mitochondria dysfunction amyotrophic lateral sclerosis clinical trial drug oxidative stress axonal transport membrane integrity apoptosis mitochondrial apoptotic pathway
Development of 6-mercaptopurine and Methotrexate oral liquid formulations for the maintenance treatment of Acute Lymphoblastic Leukæmia in children (LOULLA&PHILLA)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Collaborative project
Countries involved: France,Denmark,France,Germany,France,France,Germany,France,France,Ireland
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-11-01
End date: 2012-04-30
Duration (months): 42.0
Total project cost (EUR): 4244817.47
EU funding (EUR): 3316415.0
Participants: 12
Project status: CLOSED

Only for Children Pharmaceuticals, a French based Small and Medium-sized Enterprise (SME) developing drug for children, is the Coordinator of a multinational, multidisciplinary and complementary Consortium. This Consortium is composed of highly qualified organizations and notorious clinicians in pediatric hemato-oncology. The Consortium is an integrated team of competencies (clinicians, pædiatricians, pharmacokineticists, pharmacists, manufacturers, engineers, regulatory and ethical experts) capable of executing a pædiatric drug development from its designing to market. The Consortium will perform the non-clinical development of Methotrexate (MTX) and the non-clinical and clinical development of 6-Mercaptopurine (6MP) oral liquid formulations adapted for maintenance treatment of pediatric acute lymphoblastic leukemia with the crucial objective to make available these adapted formulation by 2012 at the latest. Methotrexate and 6-mercaptopurine are on the EMEA Priority list of off-patent medicinal products of paediatric working party of the European medicine agency - June 2007. On September 2007, EMEA’s COMP Committee has granted the orphan status to Methotrexate (oral liquid) and 6-mercaptopurine (oral liquid).

Keywords: methotrexate acute lymphoblastic leukemia mercaptopurine children genotyping trial liquid oral taste
Biochemically Equivalent Substitutive Technology for Stem Cells (BEST-STEM CELLS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: United Kingdom,United Kingdom,France,Germany,Denmark,Belgium,United Kingdom
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-07-01
End date: 2012-12-31
Duration (months): 42.0
Total project cost (EUR): 3983495.4
EU funding (EUR): 2999067.0
Participants: 8
Project status: CLOSED

Current technology to control embryonic and adult stem cell behaviour is dependent on conventional in vitro culture systems and crude factors such as serum and purified proteins, often sourced from vertebrate animal tissue. These factors contribute to variations in cell properties and differentiation potential which impact on the efficacy of cell culture. More worryingly these factors are potential avenues for the introduction of unknown or known pathogens with the capacity to infect transplant recipients thereby becoming communicable to the general population. Especially concerning is the opportunity for transmission of potentially lethal diseases across vertebrate species for which there are no known cures. The propensity of primitive stem cell populations to spontaneously differentiate is an added challenge which generally necessitates cumbersome manipulation of cells by skilled operators involving daily assessment, media replenishment and or cell passaging by physical dissociation. Realising the promise of stem cells and their derivatives for clinical and industrial applications therefore requires the evolution of new paradigms for cell culture which maximise chemical definition, minimise the involvement of skilled operators, and offer non-invasive modulation of cells by biocompatible means. The aim of this proposal is to discover and integrate with established and new cell culture technology, synthetic and non-vertebrate derived purified molecules with a capacity to mimic the functional properties of crude biological reagents currently used to control the behaviour of embryonic and adult stem cells, most notably affecting self-renewal, pluripotency, lineage specification and stability following cryopreservation. These will be validated to deliver new culture paradigms designed for compliance with Good Manufacturing Practice Standards necessary for the delivery of clinical grade cells for therapeutic use.

Keywords: chemically defined good manufacturing practice clinical grade human embryo stem cells human mesenchymal stem cells
Proteomics Standards International Molecular Exchange - Systematic Capture of Published Molecular Interaction Data (PSIMEX)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Coordination and support actions
Countries involved: Germany,Italy,United States,Switzerland,United Kingdom,Germany,Sweden,United Kingdom,Spain,Germany,Germany,France,China
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-03-01
End date: 2013-08-31
Duration (months): 54.0
Total project cost (EUR): 1748045.92
EU funding (EUR): 1476384.0
Participants: 15
Project status: CLOSED

The aim of the PSIMEx proposal is to systematically make published molecular interaction data computationally accessible. We plan to further develop the existing standard for molecular interactions developed by the HUPO Proteomics Standards Initiative, and to promote its implementation in the entire chain from experiment planning via data formatting and analysis to data representation in journal publications and public databases. Key aspects will be the dissemination of and user training on minimum requirements for publication of molecular interaction data; the further development of the PSI-MI standard for representation of data fulfilling these minimal requirements; the specification of efficient data deposition tools and data flow from data producers to public repositories as part of the publication process; implementation of international data exchange among databases; training and exchange of curation staff in the participating databases; and the definition of analysis tools for the efficient use of data following the PSI-MI standards.

Keywords: molecular interaction,systems biology,international data exchange
Copy number variations conferring risk of psychiatric disorders in children (PSYCHCNVS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Iceland,United Kingdom,Ukraine,Georgia,North Macedonia,Serbia,Russian Federation
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-01-01
End date: 2012-06-30
Duration (months): 42.0
Total project cost (EUR): 4291496.0
EU funding (EUR): 2999798.0
Participants: 8
Project status: CLOSED

The recent technical improvements for the study of the cytogenetic basis of disease have led to the identification of many microdeletion and microduplication syndromes. De novo copy number variants (CNVs) are seen more often than expected in autistic patients, and rare chromosomal aberrations are known to account for a small fraction of schizophrenia and bipolar disorder. Recurrent spontaneous mutations at multiple sites across the genome may be a prime cause of these disorders, and the reduced fertility associated particularly with autism and schizophrenia may, through selection pressure, maintain these variants at very low frequency. CNVs are large enough to be identified using cost efficient genome-wide search techniques, such as oligonucleotide arrays. In contrast, rare DNA mutations might confer a large proportion of the overall genetic risk, but cannot be easily identified at the present time. Genetic epidemiology suggests that autism, bipolar disorder, and schizophrenia are highly heritable and share susceptibility genes. However, the results of dense SNP array-based genome wide association scans for these disorders have been disappointing, as no high frequency risk alleles have been identified. The PsychCNVs consortium will apply oligonucleotide arrays for the large-scale interrogation of CNV variation in the human genome, focusing on people with autism and childhood onset schizophrenia and bipolar disorder, where CNVs are likely to be more common. This project follows on logically from our hypothesis-independent genome-wide SNP search for common variants, we now intend to systematically search for large, rare CNVs conferring high risk. The genetic risk conferred by CNVs will be estimated by genotyping samples from 2800 patients, to identify de novo or recent spontaneous mutations. Until low cost whole genome sequencing becomes available this approach offers the best current hope to identify causative genomic variants for these disorders.

Keywords: psychiatric,children,schizophrenia,bipolar disorder,autism,psychosis
Developing minimally invasive, tools and technologies for high throughput, low cost molecular assays for the early diagnosis of schizophrenia and other psychiatric disorders (SCHIZDX)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: United Kingdom,Germany,Germany,Ireland,Germany,United Kingdom,Estonia,United States
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-10-01
End date: 2012-03-31
Duration (months): 42.0
Total project cost (EUR): 3586932.2
EU funding (EUR): 2757688.0
Participants: 9
Project status: CLOSED

Schizophrenia and bipolar affective disorder are a major burden to affected individuals and their families and to society at large. These two severe mental illnesses affect at least 2% of the population worldwide, and whilst 50% of sufferers do not receive adequate treatment, they cost hundreds of billions in healthcare provision, treatments and lost earnings. The current diagnosis of schizophrenia (and bipolar disorder etc.) is rather subjective, not only because of the complex spectrum of symptoms and their similarity to other mental disorders, but also due to the lack of empirical disease markers. This result in long delays (up to 1-3 years) before appropriate therapeutics is prescribed to first episode schizophrenics. Early treatment is associated with greatly improved patient outcomes. There is therefore a major unmet clinical need for empirical diagnostic tests for high throughput screening of biological fluids that would enable early and accurate diagnosis of schizophrenia and related disorders. The identification of specific biomarkers for mental disorders would revolutionise the clinical management of affected individuals. Biomarkers will help in the identification of disease sub-types, aid in predicting and monitoring treatment response and compliance, and identify novel drug targets. If such biomarkers can be found in readily accessible body fluids they open up the possibility of developing new early or pre-symptomatic diagnostics and/or treatments to improve outcomes or even prevent disease. The objective of our project is to identify biomarkers of disease and develop a diagnostic assay panel/tool for the high throughput screening of biological samples for clinical research. Moreover this platform will be utilised by SMEs for drug design and development for mental disorders research into new animal models for mental dirders and identifying biomarkers for other mental disorders

Keywords: clinical research,proteomics,high throughput technologies,schizophrenia,bipolar disorder,mental disorders,early diagnosis
Systems biology of phagosome formation and maturation, modulation by intracellular pathogens (PHAGOSYS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: United Kingdom,Netherlands,Netherlands,Germany,Slovenia
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-11-01
End date: 2012-04-30
Duration (months): 42.0
Total project cost (EUR): 3941752.0
EU funding (EUR): 2990375.0
Participants: 5
Project status: CLOSED

To address the question of how intracellular pathogens modulate phagosome trafficking in the host cell we propose to use a systems biology approach, using an iterative cycle of experimental data, model, new experimental data, improved model. The ultimate aim of our project is to develop a mathematical model of mycobacteria and Salmonella infection of macrophages that can be applied to find new interventions that promote clearance of intracellular bacteria by phagocytic cells, and so boost innate immunity. To answer this question we have assembled a consortium of European experts able to tackle complementary aspects of this problem. By bringing together these laboratories to focus on a common goal we will be able to lever their expertise far beyond the state of the art.

Keywords: intracellular bacterial pathogens,salmonella,mycobacteria,phagocytosis,machine learning,odes